• About Us
  • TMEA Platform
  • Pipeline
  • Products
  • Partners
  • News
  • Careers
EN
English
中文
菜单
  • Home
  • About Us
  • TMEA Platform
  • Pipeline
  • Products
  • Partners
  • News
  • Careers
  • 中文
News
  1. Home
  2. News
  • Media Release
    2024/12/2 9:00:00
    Affinity Biopharma Announced the Completion of its Series B2 Financing Round Exceeding 400 Million Chinese Yuan (CNY) to Accelerate the Development of New Drugs
  • Corporate News
    2024/2/4 17:07:46
    Anglikang Pharmaceutical and Affinity Biopharma Reached Strategic Cooperation Agreement
  • Corporate News
    2022/8/9 11:19:32
    Affinity QHL-236 Legutaxel Clinical Trial Granted Approval in Australia
  • Corporate News
    2022/4/20 14:59:47
    Affinity QHL-236 Legutaxel Clinical Trial Application Granted Implied Permission
  • Corporate News
  • Media Release
  • Scientific Progress
All
  • All
  • 2021
  • 2023
  • 2024
  • 2024/12/2 9:00:00
    Affinity Biopharma Announced the Completion of its Series B2 Financing Round Exceeding 400 Million Chinese Yuan (CNY) to Accelerate the Development of New Drugs
  • 2023/7/5 10:35:54
    Affinity Biopharma Announced the Completion of B1 Round of Financing to Accelerate the Development of Innovative Product Pipelines
  • 2021/10/29 10:22:58
    Affinity Participated in the 9th Healthcare and Life Sciences Leadership Summit held by China Renaissance
  • 上一页
  • 1
  • 下一页
  • About Us
    Company Overview
    Vision & Mission
    Management Team
    Contact Us
  • TMEA Platform
    Industry Pain Points
    Widely Applicable Platform
    Versatile Platform
  • Pipeline
    Internal Pipeline
    Partnership Pipeline
  • Products
    Gelsooth Oral Biogel
  • Partners
    Business Opportunities
    Partners
  • News
    Corporate News
    Media Release
    Scientific Progress
  • Careers
    Careers
  • Follow us to learn more
Copyright - Shanghai Affinity Biopharmaceutical Co.,Ltd. All Rights Reserved.    沪ICP备2022005440号-1
Terms of use Privacy policy